Pentoxifylline Tablets – Manufacturer & Exporter India

1. Product Introduction

Pentoxifylline is a hemorheologic agent used for symptomatic treatment of intermittent claudication associated with chronic occlusive peripheral arterial disease. It can improve blood flow characteristics by affecting red blood cell flexibility and blood viscosity. Symptomatic improvement may be modest; treatment does not replace smoking cessation, supervised exercise, vascular risk-factor management or assessment for revascularization when indicated.

Healthy Life Pharma Pvt. Ltd. is identified in the supplied company information as manufacturer and Healthy Inc as exporter. Manufacturing approvals, exact dosage-form release characteristics and certification status should be confirmed against current product documents.

2. Product Specifications

3. Manufacturing Technology

For an approved extended-release pentoxifylline tablet, formulation development must control the drug-release profile throughout the intended dosing interval. Hydrophilic polymer matrices, including HPMC, are one possible platform, but use of any particular polymer or technology must be confirmed from actual manufacturing records.

Film-coating integrity, blend uniformity, compression controls and moisture protection should be evaluated as applicable. Do not describe a specific 12-hour release system, matrix polymer or blister material as an established product feature without validation.

4. Quality Assurance

Product-specific testing should follow the applicable approved pharmacopoeial or in-house specification, including identity, assay, dosage-unit uniformity, impurities and stability. Where extended release is approved, dissolution testing at multiple time points and assessment of dose-dumping risks are especially important.

Exact acceptance limits, release intervals and validated analytical methods must come from the approved specification; universal numerical assay or dissolution limits are not appropriate.

5. Therapeutic Information

Primary use: symptomatic treatment of intermittent claudication due to chronic peripheral arterial disease, where authorized. Pentoxifylline influences the rheological properties of blood, including erythrocyte deformability. Its clinical benefit for walking distance is variable, and guideline recommendations differ.

Use for venous leg ulcers is an additional context supported in some clinical practice settings, but is separate from the primary approved indication and depends on local authorization. Pentoxifylline should not be promoted for alcoholic hepatitis as routine therapy.

6. Export and Regulatory Support

Importers and distributors may enquire about product registration status, contract manufacturing, approved strength and release type, batch size, packaging, country-specific labeling, stability documentation and shipment terms. CTD/ACTD dossiers, COPP, FSC, COA, WHO-GMP and Star Export House claims require current documentary verification before they are represented as available or certified.

7. Frequently Asked Questions

What is Pentoxifylline used for? It is used for symptoms of intermittent claudication associated with peripheral arterial disease where approved.

Can an extended-release tablet be crushed? No. An ER tablet should generally be swallowed whole; crushing can alter release. Confirm whether the actual 400 mg film-coated product is ER from its approved label.

How soon can benefit be noticed? Symptom improvement may take several weeks and is not guaranteed. Follow the approved product information and clinician assessment.

Is Pentoxifylline an anticoagulant? It is primarily a hemorheologic agent, not a substitute for prescribed anticoagulants or antiplatelet therapy. Bleeding precautions may apply, particularly with interacting medicines.

8. Dosage and Administration

Use the exact dosage schedule stated in the approved local product information and prescribed by a clinician. Some approved 400 mg extended-release products are administered with meals, but dosing frequency and adjustments depend on kidney function, tolerability and the specific formulation. Do not crush or chew an extended-release tablet.

9. Side Effects and Precautions

Possible adverse effects include nausea, vomiting, dyspepsia, headache, dizziness and flushing. Use caution in patients with bleeding risk, recent bleeding, renal impairment, cardiovascular disease or concomitant anticoagulant/antiplatelet medicines. Important contraindications and interactions must be checked against the locally approved label. Seek urgent medical care for significant bleeding, severe allergic symptoms, fainting or chest pain.

10. Storage Instructions

Store according to the approved package label in the original packaging, protected from inappropriate heat and moisture and out of reach of children. The proposed storage temperature and 24–36 month shelf life require supporting stability data and should not be presented as verified.